News

How a combined ophthalmology/rheumatology uveitis clinic collaborates to monitor systemic disease activity and tolerance to systemic therapy

Technologies offer different approaches to different scenarios

Eyes with chronic disease responded to steroid treatment

Investigators set out to determine if treatment crosses blood-retina barrier

Worldwide increase in technologies for ophthalmic use is dramatic

Fluocinolone acetonide implant for DME benefits visual acuity

For ophthalmologists, the interactive landscape of surgical visualization, including 3D digital surgery, robotics, and an OCT-enriched surgical theater, is leading to new opportunities.

Numerous studies will be completed during the next few years, and many new studies are being developed.

Studying zebrafish helps unravel mysteries of photoreceptor regeneration

This novel intravitreal gene therapy may also hold potential for the treatment of diabetic macular edema.

Studies highlight the need for specialists and training programs focusing on the disease.

Technology helps physicians understand normal and abnormal macular anatomy

Key is to recognize usual patterns for systemic and topical medications

Transient sensory-motor abnormalities are often common

Injections and implants continue to create further positive outcomes for patients.

Novel option demonstrates stable to improved visual acuity and retinal thickness

Minimizing clinic visits, maximizing use of imaging modalities are key

Options for physicians are increasing in availability, with fewer costs and travel burdens for patients

Ophthalmologist provides patient counseling pearls for selected retinal dystrophies

Novel gene therapy/medical device combo sheds light on retina in RP

Study highlights role of demographic and socioeconomic characteristics in treatment

Rapid fluid identification may result in better visual outcomes

Specialist explains approaches for a variety of cases encountered during procedure

According to investigators at the Wilmer Eye Institute at the Johns Hopkins University School of Medicine conducting experiments in mouse tissues and human cells, by removing a membrane that lines the back of the eye they may be able improve the success rate for regrowing nerve cells damaged by blinding diseases.

Annual Bascom Palmer Eye Institute program will spotlight latest advances in neovascular and exudative ocular disease over 2-day event, February 12-13.

Three sessions cover the range from clinical updates for imaging to emerging therapies for non-exudative AMD.

The program features an update on faricimab, plus diabetes, choroiditis, retinitis pigmentosa, and late-breaking reports.

John H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his story.